Goldman Sachs Initiates Coverage On Arrowhead Pharma with Neutral Rating, Announces Price Target of $31
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has initiated coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Neutral rating and set a price target of $31.
June 05, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs has initiated coverage on Arrowhead Pharma with a Neutral rating and a price target of $31. This suggests that the firm sees limited upside potential in the short term.
The Neutral rating indicates that Goldman Sachs does not expect significant movement in Arrowhead Pharma's stock price in the near term. The price target of $31 suggests that the stock is fairly valued at its current price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100